Media & Resources

The International AIDS Vaccine Initiative and the Ragon Institute Signed Memorandum of Understanding to Collaborate on AIDS Vaccine Research NEW YORK, October 16, 2009 ─The International AIDS Vaccine Initiative (IAVI) announced today that it has signed a memorandum of understanding with the Ragon Institute to accelerate the development of new and promising AIDS vaccine candidates…

NEW YORK, NY, SEPTEMBER 24, 2009 –The International AIDS Vaccine Initiative (IAVI) greeted with excitement today’s announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combination of two AIDS vaccine candidates has shown partial efficacy in a phase III efficacy trial…

LA JOLLA, CA and NEW YORK, NY September 24, 2009 – Today, the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute officially launched a new research center, the IAVI Neutralizing Antibody Center at The Scripps Research Institute.  Scientists at the Neutralizing Antibody Center will focus on designing AIDS vaccines that elicit antibodies that…

Findings Reveal an Achilles Heel on the Virus for AIDS Vaccine Researchers to Exploit  NEW YORK, NY, LA JOLLA and SAN FRANCISCO, CA, SEATTLE, WA, September 3, 2009—Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered…

NEW YORK, August 19, 2009─Dianne Stewart, former head of Board and Donor relations at the Global Fund to Fight AIDS, Tuberculosis and Malaria, has joined the International AIDS Vaccine Initiative (IAVI) as Vice President of Resource Development.  In her role at IAVI, Ms. Stewart will provide leadership for the organization’s fundraising strategy focused on both…

 August 6, 2009. For the eighth consecutive year, the International AIDS Vaccine Initiative (IAVI) has received a four-star rating from Charity Navigator, America’s largest independent evaluator of charities. This rating indicates that IAVI, a nonprofit organization dedicated solely to AIDS vaccine development, excels in managing its finances efficiently and effectively. That is to say, nearly…

Shifting scientific, health priorities and global economic downturn impact investment in HIV prevention R&D Cape Town – A new report on investment in HIV prevention research in 2008 finds that HIV vaccine research funding levels decreased for the first time since investment trends have been tracked. This may have been influenced by shifts in scientific…

SEATTLE & NEW YORK–(BUSINESS WIRE)–Theraclone Sciences, Inc. and the International AIDS Vaccine Initiative (IAVI) have announced an expansion of their HIV antibody discovery program. In 2008, Theraclone was granted an award under IAVI’s Innovation Fund to test its unique process for isolating, from the blood of certain HIV-infected individuals, potent monoclonal antibodies to HIV that…